



## **W Fraser Symmans**

### **Kontakt**

W Fraser Symmans

## Publikationen (3)

Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. *NPJ Breast Cancer* 2021; 7:142.

Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7:603-608.

Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. *Lancet Oncol* 2018; 19:497-509.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)